Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Olema Pharmaceuticals (NASDAQ:OLMA) had its target price increased by equities research analysts at JPMorgan Chase & Co. from $55.00 to $58.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 304.04% from the company’s current price.

Several other equities research analysts have also recently commented on the company. Oppenheimer reissued an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. The Goldman Sachs Group cut their price objective on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Finally, UBS Group began coverage on shares of Olema Pharmaceuticals in a report on Wednesday, January 7th. They set a “buy” rating and a $45.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.89.

Olema Pharmaceuticals Stock Down 4.7%

OLMA traded down $0.71 during trading on Wednesday, reaching $14.36. 329,800 shares of the stock traded hands, compared to its average volume of 1,609,504. The stock’s 50-day simple moving average is $23.81 and its two-hundred day simple moving average is $18.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The stock has a market cap of $985.61 million, a price-to-earnings ratio of -7.71 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, March 16th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.01. As a group, equities research analysts expect that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Activity at Olema Pharmaceuticals

In related news, Director Ian T. Clark sold 264,800 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $29.73, for a total transaction of $7,872,504.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 805,501 shares of company stock valued at $23,003,832. 16.36% of the stock is owned by company insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several large investors have recently bought and sold shares of OLMA. Nisa Investment Advisors LLC lifted its position in Olema Pharmaceuticals by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Olema Pharmaceuticals by 8.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock valued at $325,000 after buying an additional 987 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Olema Pharmaceuticals by 44.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Olema Pharmaceuticals by 13.8% during the 4th quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after acquiring an additional 1,740 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

More Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised multiple near‑ and long‑term EPS estimates (Q1–Q4 2026 and FY2026–2030) and reiterated a Buy rating with a $38 price target — an analyst upgrade thread that supports upside expectations by trimming projected losses per share. HC Wainwright estimates (MarketBeat)
• Positive Sentiment: Citigroup raised its price target from $60 to $62 and kept a Buy rating, signaling strong bullish conviction from a major bank and providing a high‑profile bullish anchor for investors. Citigroup price‑target raise (Benzinga)
• Positive Sentiment: Recent Q4 results topped expectations and previously triggered an intraday jump (~9% noted in coverage), reinforcing the narrative that clinical/operational news can move the stock quickly. Earnings surprise drove a stock jump (Blockonomi)
• Positive Sentiment: A large $68.7M external bet reported on the company (coverage tied to its breast‑cancer program aimed at a 2027 launch) highlights significant investor interest/capital flows into Olema’s clinical story. That headline can attract momentum buyers if development milestones remain on track. Large investor bet (The Globe and Mail)
• Neutral Sentiment: Olema will present preclinical data for palazestrant and OP‑3136 at the 2026 AACR meeting — a near‑term scientific catalyst that could be stock‑moving depending on data content, but outcome uncertainty keeps this neutral until results are public. AACR presentation (Business Insider)
• Neutral Sentiment: Technical note: a recent Zacks piece flags the stock as having fallen sharply and entering oversold territory, suggesting selling pressure may be near exhaustion — a potential contrarian indicator but not a guaranteed reversal. Oversold / trend commentary (Zacks)
• Negative Sentiment: Goldman Sachs cut its price target from $38 to $27 (while keeping a Buy rating), trimming potential upside and introducing near‑term selling pressure as some investors mark positions to lower analyst targets. Goldman Sachs PT cut (Benzinga)
• Negative Sentiment: Guggenheim lowered its price target from $40 to $38 (still Buy), another downward revision that can damp momentum and contribute to intra‑day weakness when combined with profit‑taking. Guggenheim PT cut (Benzinga)

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.